CLOs on the Move


 
Artel is the global technology leader in ultra low volume liquid delivery measurement and quality assurance. The company develops and manufactures the most accurate, precise and easy-to-use systems available for ensuring liquid delivery data integrity and NIST-traceable results in life sciences laboratories. Artel innovations help laboratories improve processes and increase productivity, enhance product quality, and address compliance challenges.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Smith-Sterling Dental Laboratories

Smith-Sterling Dental Laboratories is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

Green Point Research

Working to cultivate a better tomorrow by bringing together human, natural & financial resources to grow our businesses and communities.